Imaging study of diabetes drugs and body changes
Part of Hormones & metabolism clinical trials.
This study is looking at how certain diabetes medications affect the body's makeup (like muscle and fat) and how the body works, using special imaging scans. It may help doctors understand these treatments better and could guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have type 2 diabetes.
- You recently started taking semaglutide (like Ozempic or Wegovy) or tirzepatide (like Mounjaro) under a doctor's care.
- You can speak and read English.
- You are not pregnant or breastfeeding.
- Your weight has been fairly stable recently (no gain or loss of more than about 11 pounds before starting the medication).
- You have not had weight-loss surgery in the past, and you are not planning to have it within the next year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses special MRI scans to see how the diabetes medication semaglutide affects muscles and fat. If you are starting semaglutide for type 2 diabetes, this research may help doctors understand how the medicine works.
This study looks at differences in body fat to understand why some people develop type 2 diabetes. You may be asked for blood tests and health information to see if your diabetes risk and body fat patterns are linked.
This study uses a special full-body PET scan to see how two natural hormones, GIP and GLP-1, affect how your body uses sugar and moves blood. It includes healthy volunteers and people with type 2 diabetes who are on metformin only.
This study tests a new medicine called zenagamtide for adults with overweight or obesity, with or without type 2 diabetes, who are currently taking semaglutide. The goal is to see how well people tolerate switching from semaglutide to the new treatment.
This study tests if adding LY3457263 helps lower blood sugar in people with type 2 diabetes who are already taking a stable dose of semaglutide or tirzepatide. You will be randomly assigned to get either LY3457263 or a placebo.
This study compares how a GLP-1 medication (a drug that helps control blood sugar and weight) changes the way your body stores and uses fat. Researchers will use imaging scans to see these changes over time in people with metabolic syndrome—a cluster of health conditions including high blood pressure, high cholesterol, and excess weight.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.